Astrocyte-secreted glypican-4 drives APOE4-dependent tau hyperphosphorylation
Open Access
- 15 August 2022
- journal article
- research article
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 119 (34)
Abstract
Tau protein aggregates are a major driver of neurodegeneration and behavioral impairments in tauopathies, including in Alzheimer’s disease (AD). Apolipoprotein E4 ( APOE4 ), the highest genetic risk factor for late-onset AD, has been shown to exacerbate tau hyperphosphorylation in mouse models. However, the exact mechanisms through which APOE4 induces tau hyperphosphorylation remains unknown. Here, we report that the astrocyte-secreted protein glypican-4 (GPC-4), which we identify as a binding partner of APOE4, drives tau hyperphosphorylation. We discovered that first, GPC-4 preferentially interacts with APOE4 in comparison to APOE2, considered to be a protective allele to AD, and second, that postmortem APOE4-carrying AD brains highly express GPC-4 in neurotoxic astrocytes. Furthermore, the astrocyte-secreted GPC-4 induced both tau accumulation and propagation in vitro. CRISPR/dCas9-mediated activation of GPC-4 in a tauopathy mouse model robustly induced tau hyperphosphorylation. In the absence of GPC4, APOE4-induced tau hyperphosphorylation was largely diminished using in vitro tau fluorescence resonance energy transfer-biosensor cells, in human-induced pluripotent stem cell-derived astrocytes and in an in vivo mouse model. We further show that APOE4-mediated surface trafficking of APOE receptor low-density lipoprotein receptor-related protein 1 through GPC-4 can be a gateway to tau spreading. Collectively, these data support that APOE4-induced tau hyperphosphorylation is directly mediated by GPC-4.Keywords
Funding Information
- HHS | National Institutes of Health (K01AG062683, U01AG058635, R01AG064020, U19AG069701)
This publication has 68 references indexed in Scilit:
- Astrocyte glypicans 4 and 6 promote formation of excitatory synapses via GluA1 AMPA receptorsNature, 2012
- Propagation of Tau Pathology in a Model of Early Alzheimer's DiseaseNeuron, 2012
- Heparan Sulphate Proteoglycan and the Low-Density Lipoprotein Receptor-Related Protein 1 Constitute Major Pathways for Neuronal Amyloid-β UptakeThe Journal of Neuroscience, 2011
- Heparan sulfate mediates amyloid-beta internalization and cytotoxicityGlycobiology, 2010
- Apolipoprotein E ε4 is associated with disease-specific effects on brain atrophy in Alzheimer's disease and frontotemporal dementiaProceedings of the National Academy of Sciences, 2009
- Redefining the concept of reactive astrocytes as cells that remain within their unique domains upon reaction to injuryProceedings of the National Academy of Sciences, 2006
- Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer diseaseNature Genetics, 1994
- Confirmation of association between the e4 allele of apolipoprotein E and Alzheimer's disease.Journal of Medical Genetics, 1994
- Gene Dose of Apolipoprotein E Type 4 Allele and the Risk of Alzheimer's Disease in Late Onset FamiliesScience, 1993
- Neuropathological stageing of Alzheimer-related changesActa Neuropathologica, 1991